Drugs / Camu Camu
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06049576 | Oct 2023 → Jun 2026 overdue | clear cell renal carcinoma, sarcomatoid renal cell carcinoma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05303493 | Jun 2022 → Jul 2025 | melanoma, non-small cell lung carcinoma | University of Montreal Hospital Centre (CHUM) | Completed | No outcome recorded |
| Phase 1 | NCT04058392 | Nov 2020 → Jul 2022 | HIV infectious disease | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Camu Camu | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05303493 ↗ |
| Known as | Myrciaria dubia | “the berry Camu Camu (CC), also known as Myrciaria dubia has prebiotic potential to enrich Akkermansia muciniphila” NCT05303493 ↗ |
| Route | Oral | “CC oral supplementation significantly decreased tumor size” NCT05303493 ↗ |